Etanercept-associated Myelitis
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Drug-related immune-mediated myelopathies.
Gritsch D, Valencia-Sanchez C Front Neurol. 2022; 13:1003270.
PMID: 36247761 PMC: 9557103. DOI: 10.3389/fneur.2022.1003270.
[Differential diagnostics of autoimmune inflammatory spinal cord diseases].
Oertel F, Scheel M, Chien C, Bischof A, Finke C, Paul F Nervenarzt. 2021; 92(4):293-306.
PMID: 33765163 PMC: 7992127. DOI: 10.1007/s00115-021-01092-2.
References
1.
Solomon A, Spain R, Kruer M, Bourdette D
. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler. 2011; 17(12):1472-87.
DOI: 10.1177/1352458511412996.
View
2.
Alessandri C, Scrivo R, Spinelli F, Ceccarelli F, Magrini L, Priori R
. Autoantibody production in anti-TNF-alpha-treated patients. Ann N Y Acad Sci. 2007; 1110:319-29.
DOI: 10.1196/annals.1423.034.
View
3.
. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1999; 53(3):457-65.
View
4.
Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G
. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology (Oxford). 2013; 52(5):868-74.
DOI: 10.1093/rheumatology/kes375.
View
5.
van Oosten B, Barkhof F, Truyen L, Boringa J, Bertelsmann F, von Blomberg B
. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996; 47(6):1531-4.
DOI: 10.1212/wnl.47.6.1531.
View